

Novo Nordisk announces launch of injectable Semaglutide for weight management in India

24 June 2025 | News

Wegovy® - once-weekly injectable weight management medication - now available in India



Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy® (injectable Semaglutide) in India.

Wegovy® - a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) - is the first and only weight management medication in India indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events in people living with the condition. It is available in five dosing strengths with the convenience of an innovative easy-to-use pen device.

Wegovy® is a prescription-only medication that has the potential to improve the quality of life for millions of Indians living with obesity or overweight. As per the INDIAB study, India has 254 million people with generalised obesity and 351 people with abdominal obesity.

Semaglutide is the active ingredient in both Ozempic® and Wegovy®. While Ozempic® in many countries across the world is indicated for the treatment of adults with insufficiently controlled type 2 diabetes, Wegovy® is indicated for weight management and reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Ozempic® is not yet available in India. It is strongly advised that people with overweight or obesity speak to their doctor for appropriate treatment options.

Vikrant Shrotriya - Managing Director, Novo Nordisk India said, "Obesity is not just a personal health concern—it is a chronic disease and a national epidemic that India cannot afford to ignore. Recognising this, we are proud to announce that we are bringing Wegovy® to Indians as a transformative and evidence-based therapeutic solution with the convenience of a world-class, state-of-the-art pen device. Additionally, we have an India-specific price with the benefit of same price for the first three dosing strengths. With this we are reaffirming our commitment to address India's growing burden of overweight and obesity."

Wegovy® will be available in a once-weekly innovative pen device in five dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a maintenance dosing of 2.4 mg. The state-of-the-art pen device provides the convenience of simple administration and

precise dosing.